Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences announces first quarter 2016 results

Canada NewsWire May 11, 2016

ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease

Canada NewsWire May 5, 2016

ProMIS Neurosciences, Inc. Successfully Completes CDN $1.0 Million Private Placement

Canada NewsWire May 4, 2016

ProMIS Neurosciences, Inc. Completes First Tranche of its Private Placement

Canada NewsWire March 30, 2016

ProMIS Neurosciences announces FY2015 year end results

Canada NewsWire March 23, 2016

ProMIS Neurosciences announces identification of a third novel therapeutic target for Alzheimer's disease

Canada NewsWire March 18, 2016

ProMIS Neurosciences announces private placement

Canada NewsWire February 23, 2016

ProMIS Neurosciences announces identification of a second novel therapeutic target for Alzheimer's disease

Canada NewsWire February 3, 2016

ProMIS(TM) Neurosciences announces formation of prestigious Scientific Advisory and Business Advisory Boards

Canada NewsWire January 26, 2016

ProMIS Neurosciences adopts shareholder rights plan

Canada NewsWire January 25, 2016

ProMIS Neurosciences announces acquisition of exclusive worldwide license to novel therapeutic target for Alzheimer's disease

Canada NewsWire November 12, 2015

ProMIS Neurosciences acquires exclusive worldwide license to Collective Coordinates, a new method to identify novel therapeutic targets for Alzheimer's disease

Canada NewsWire November 11, 2015

ProMIS Neurosciences announces third quarter results for period ending September 30, 2015

Canada NewsWire November 10, 2015

ProMIS Neurosciences Announces Educational Webcast Entitled "Alzheimer's, Light at the End of the Tunnel"

Canada NewsWire October 27, 2015

ProMIS Neurosciences Announces Expanded License Agreement with The University of British Columbia

Canada NewsWire October 8, 2015

ProMIS Neurosciences Announces that Chief Scientific Officer, Dr. Neil Cashman, to Address Annual Meeting of the American Neurological Association (ANA)

Canada NewsWire September 29, 2015

ProMIS Neurosciences announces second quarter results for period ending June 30, 2015

Canada NewsWire August 13, 2015

ProMIS Neurosciences, having raised the maximum authorized amount of CDN $2.5MM, announces closing of the second and final tranche of the Private Placement Offering announced May 22, 2015

Canada NewsWire August 4, 2015

ProMIS Neurosciences, having raised the maximum authorized amount of CDN $2.5MM, announces closing of the second and final tranche of the Private Placement Offering announced May 22, 2015

Canada NewsWire August 4, 2015

ProMIS Neurosciences, having raised the maximum authorized amount of CDN $2.5MM, announces closing of the second and final tranche of the Private Placement Offering announced May 22, 2015

Canada NewsWire August 4, 2015